Show MeYes, methotrexate can cause lung problems, and they fall into three distinct categories that carry very different risks. Direct drug-induced lung injury (methotrexate pneumonitis) is the rarest but most dangerous, striking roughly 0.3 to 1 percent of rheumatoid arthritis patients on low-dose therapy. Opportunistic lung infections are more common because methotrexate suppresses immune defense. Accelerated nodulosis is a benign but alarming edge case where lung nodules multiply on treatment. Most people who take methotrexate never develop lung disease, but the drug can inflame, scar, or make the lungs vulnerable to infection in a meaningful minority.
How Methotrexate Reaches and Irritates Lung Tissue
Methotrexate works by blocking dihydrofolate reductase, an enzyme that recycles folate into the building blocks of DNA. Rapidly dividing cells feel this first, which is why the drug calms overactive immune cells in rheumatoid arthritis and psoriasis and why it stalls cancer growth at high doses.
The lung connection is less obvious. Methotrexate concentrates inside cells by adding glutamate chains, a process called polyglutamation. Lung tissue retains these polyglutamated forms far longer than blood does, so the drug's intracellular half-life in the lung can stretch to days or weeks rather than hours. That persistence is one reason a reaction can appear months after a dose change, not just days.
The leading mechanism for methotrexate pneumonitis is a hypersensitivity reaction, not direct chemical burn. The immune system mounts an allergic-type inflammatory response inside the alveolar spaces, flooding them with lymphocytes and eosinophils. In plain terms: the drug doesn't poison the lung directly so much as trigger the body's own immune cells to attack lung tissue.
A competing mechanism involves folate depletion in lung epithelial cells, which may impair repair and lower the threshold for injury. Which mechanism dominates in any single patient is still debated, so treat the hypersensitivity explanation as the leading hypothesis rather than settled fact.
How Common Are Lung Problems on Methotrexate?
The numbers depend heavily on which lung problem you count and which patient population you study. Rheumatoid arthritis patients dominate the literature because they take the drug longest, but they also have higher baseline lung disease than the general population.
| Lung problem | Estimated frequency | Typical onset | Reversible? |
|---|---|---|---|
| Methotrexate pneumonitis | 0.3–1% of RA patients (some series up to 5%) | Weeks to months; can be years | Often, if caught early |
| Opportunistic infection (PCP, viral) | 1–3% without prophylaxis in high-risk groups | Any time on therapy | Yes with treatment |
| Accelerated nodulosis | Under 1% of RA patients | Months into therapy | Partly; nodules may persist |
| Pleural effusion | Rare, usually linked to RA itself | Variable | Yes with drug hold |
| Pulmonary fibrosis (causal link unproven) | Uncertain | Years | No |
Per a landmark review by Imokawa and colleagues in 2000, roughly two-thirds of pneumonitis cases improve after stopping the drug, but mortality in reported hospital series has ranged from 1 to 17 percent. The wide spread reflects how sick the patients were at diagnosis, not how toxic the drug is on average. For comparison, the annual risk of serious infection on methotrexate monotherapy is about 1 to 2 percent, while adding a biologic roughly doubles that figure.
The pneumonitis rate deserves context. Rheumatoid arthritis itself causes interstitial lung disease in 5 to 10 percent of patients regardless of treatment, so some "methotrexate lung" cases are actually disease-driven. Separating the two is one of the hardest calls in rheumatology.
The Timeline: When Lung Problems Actually Appear
Onset is scattered and idiosyncratic, which makes calendar-based screening unreliable. The table below reflects the typical window in which each problem is diagnosed, not the moment it began.
| Time on methotrexate | What tends to appear | Key number |
|---|---|---|
| First 2–6 weeks | Hypersensitivity pneumonitis can strike early | Up to 25% of cases present in the first months |
| 2–6 months | Most pneumonitis cases diagnosed; accelerated nodules emerge | Peak incidence window |
| 6–12 months | Ongoing pneumonitis risk; first PCP infections in high-risk patients | Risk persists, does not fade |
| 1–3 years | Infection risk accumulates with cumulative dose | No hard cutoff |
| 3–5 years | Nodulosis and gradual fibrosis concerns surface | Nodules under 1% |
| Beyond 5 years | Background RA lung disease dominates; drug role harder to assign | Confounding rises |
A crucial caveat: pneumonitis has been reported from a single 7.5 mg weekly dose and after years of stable therapy. There is no safe month. The timeline shows where risk concentrates, not when it ends.
Methotrexate Pneumonitis: The Signature Presentation
Pneumonitis is the reaction most people mean when they ask about methotrexate and lungs, and it has a recognizable clinical fingerprint. Patients develop dry cough, breathlessness on exertion, and sometimes fever, often with no obvious infection. Symptoms typically build over days to a few weeks rather than hours.
The diagnostic challenge is that methotrexate pneumonitis looks like infection on a chest X-ray and like many other conditions on CT. Imaging usually shows diffuse ground-glass opacities or interstitial infiltrates. Blood tests may show eosinophilia or elevated inflammatory markers, but neither is reliable.
The strongest diagnostic clue is the response to stopping the drug. Per the 2008 British Society for Rheumatology guidelines, the working case definition requires acute onset, absence of infection, and improvement after withdrawal. That means the diagnosis is often confirmed retrospectively, by watching the patient get better off treatment.
This is why the "drug holiday" is both test and treatment. If symptoms and imaging resolve within four to eight weeks of stopping methotrexate, pneumonitis becomes the leading explanation. If they don't, another cause deserves pursuit.
Opportunistic Infections: The Underappreciated Threat
Methotrexate's immune suppression opens the door to organisms a healthy lung would clear. The most feared is Pneumocystis jirovecii pneumonia (PCP), a fungal infection that causes progressive breathlessness and low oxygen. PCP mortality in immunosuppressed patients can reach 30 to 50 percent if treatment is delayed, which makes it a genuine emergency rather than a slow-burn concern.
Risk climbs with higher doses, with combination therapy using corticosteroids or biologics, and in older patients with existing lung disease. Some centers give prophylactic antibiotics to patients on methotrexate plus high-dose steroids, though routine prophylaxis for methotrexate alone is not standard.
Nodulosis is a separate curiosity. Patients with rheumatoid arthritis who already have lung nodules sometimes see them grow or multiply after starting methotrexate. The nodules are usually benign, but new nodules must be distinguished from malignancy and infection, which requires imaging and sometimes biopsy. Stopping the drug helps in some cases but not all.
Who Is at Highest Risk?
Not everyone faces the same odds. A cluster of risk factors pushes the probability of lung trouble upward, and knowing them changes how closely you should be watched.
Age over 60 roughly doubles the relative risk in most case series. Pre-existing interstitial lung disease, common in rheumatoid arthritis, is the single strongest predictor. Smoking, prior methotrexate lung reactions, and diabetes add further risk.
Kidney function matters more than most patients realize. Methotrexate is cleared renally, so even mild kidney impairment raises blood levels and prolongs exposure. Dosing errors, especially taking daily instead of weekly doses, cause the most severe toxicity and are a recurring cause of life-threatening events.
In plain terms: the drug is safest in younger, non-smoking patients with healthy kidneys and clear lungs, and it needs tighter surveillance everywhere else.
Warning Signs You Must Not Ignore
Red-flag symptoms are the practical payoff of all this mechanism. Contact your prescriber urgently, and stop the drug only as instructed, if you develop any of the following:
- New or worsening breathlessness, especially on exertion
- A dry cough lasting more than a week without a clear cold cause
- Fever with breathlessness, which raises PCP concern
- Low oxygen readings on a home pulse oximeter (below 94 percent at rest)
- Chest pain or coughing up blood
- Any breathing change after a dose increase
Never restart methotrexate after a suspected lung reaction without a formal assessment. Re-challenge has caused severe and fatal recurrences.
What to Actually Do: Monitoring and Safe Use
Concrete actions reduce risk more than fear does. Before starting, get a baseline chest X-ray and lung function test if you have any respiratory symptoms or a history of lung disease. Per the 2022 American College of Rheumatology guidelines, baseline labs should include kidney and liver function, which govern how safely the drug clears.
Take folic acid as prescribed, since it reduces several side effects, though evidence that it prevents pneumonitis is weak. Report every breathing change promptly rather than waiting for your next visit. Keep lab monitoring on schedule, because kidney decline silently raises drug levels.
If pneumonitis is suspected, the standard approach is to stop methotrexate immediately and evaluate for infection, sometimes with bronchoscopy. Corticosteroids are often used for the inflammatory component, though their benefit is based on experience rather than large trials.
Limits of the Evidence and Misconceptions
Several beliefs about methotrexate lung risk are overstated or wrong. The idea that the drug invariably causes lung scarring is not supported. Most studies have failed to show that methotrexate causes pulmonary fibrosis, and some suggest it may slow RA-related lung disease progression.
The belief that low-dose methotrexate is harmless to lungs is equally wrong. Pneumonitis has occurred at 7.5 mg weekly, well below cancer doses.
The belief that a normal chest X-ray rules out trouble is misleading. Early pneumonitis and PCP can look subtle, and CT is more sensitive.
Finally, causation is genuinely uncertain in many cases because RA lung disease, infection, and drug reaction overlap. Honest medicine admits this. The risk is real but modest, the warning signs are learnable, and prompt action converts most scary scenarios into recoverable ones.